CAS: 135034-10-5; 3-Chloro-6-Iodopyridazine

相似化合物

856847-77-3 141-30-0 20698-04-8

上下游产品

CAS号141-30-0 3,6-二氯哒嗪 | CAS号17973-86-3 3,6-二溴哒嗪 | CAS号1120-95-2 3-氯哒嗪 | CAS号2166-07-6 3,6-bis(4-metho... | CAS号58059-31-7 3-氯-6-(4-甲氧苯基)哒嗪 | CAS号35857-89-7 6-氯-3-哒嗪甲腈 | CAS号2165-06-2 3-氯-6-邻-甲苯哒嗪 | CAS号66549-34-6 3-CHLORO-6-(3-M... | CAS号258506-68-2 3-氯-6-三氟甲基哒嗪 | CAS号20375-65-9 3-氯-6-苯基哒嗪 | CAS号76970-14-4 3-CHLORO-6-(3-M... | CAS号66548-88-7 3-氯-6-[4-(三氟甲基)苯基]吡嗪 | CAS号78784-66-4 3-Chloro-6-pyri...

📜3,6-二溴哒嗪置于氢碘酸,Sodium Iodide,Sodium Hydroxide体系中,用 水 用作溶剂,化学反应 18.0H,反应生成3-氯-6-碘哒嗪
参考文献:Wo2007/22937
标题:Wo2007/22937

专利信息

专利号:WO-2013054302-A1
优先权日:2011-10-12
标 题:Method for preparing triaryl(heteroaryl)bismuths, and uses thereof for the synthesis of aromatic or heteroaromatic derivatives
发明人：CONDON SYLVIE; URGIN KARENE; LEONEL ERIC; AUBE CHRISTOPHE; DUBREUIL DIDIER
权利人:CENTRE NAT RECH SCIENT; UNIV PARIS VAL DE MARNE; UNIV NANTES I; CONDON SYLVIE; URGIN KARENE; LEONEL ERIC; AUBE CHRISTOPHE; DUBREUIL DIDIER
摘要:The invention relates to a method for preparing a derivative of formula (I): (A) 3 -Bi, where the A groups, identical or different, are an aryl or heteroaryl radical, optionally substituted by at least one FG group, which can occupy any position on the aryl or heteroaryl ring, two FG groups occupying the same position where appropriate, FG being an electron-donating group or an electron-withdrawing group on the aryl or heteroaryl radical, by reacting an organozinc compound of formula (II): A-Zn-X, where A is as defined above and X is a halogen, with bismuth trichloride BiCl 3 , which leads to the derivative of formula (I) above. The invention can be used for synthesising bifunctionalised derivatives that can be aromatic or heteroaromatic, optionally halogenated, or polyheteroaromatic.

专利号:US-2024239799-A1
优先权日:2021-04-02
标 题:(s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
发明人：DI FABIO ROMANO; MONTALBETTI CHRISTIAN; PETROCCHI ALESSIA; GRILLO ALESSANDRO; RANDAZZO PIETRO; ROSSETTI ILARIA; CIAMMAICHELLA ALINA
权利人:C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING; IRBM S P A
摘要:The present invention relates to compounds of formula (I). The compounds of the formula (I) are e.g. (S)-1-(5-((pyridin-3-yl)thio) pyrazin-2-yl)-41H,6′H-spiro[piperidine-4,5′-pyrrolo[1,2-b]pyrazol]-41-amine derivatives and similar compounds. The present invention also relates to the compounds of formula (I) for use as Src homology phosphotyrosine phosphatase 2 (SHP2) inhibitors in methods of treatment of e.g. cancer, cardiovascular diseases, immunological disorders, autoimmune disorders, fibrosis, ocular disorders, systemic lupus erythematosus, diabetes, neutropenia, and combinations thereof. The present invention also relates to pharmaceutical compositions containing said compounds and to their methods of synthesis.

专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9187522-B2
优先权日:2011-12-12
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC
摘要:The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9598430-B2
优先权日:2013-06-11
标 题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC; CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.